| Title |
Persistence of Antipsychotic Treatment in Elderly Dementia Patients: A Retrospective, Population-Based Cohort Study
|
|---|---|
| Published in |
Drugs - Real World Outcomes, May 2016
|
| DOI | 10.1007/s40801-016-0073-6 |
| Pubmed ID | |
| Authors |
Gavin Mast, Kimberly Fernandes, Mina Tadrous, Diana Martins, Nathan Herrmann, Tara Gomes |
| Abstract |
Antipsychotics are commonly used to manage behavioral and psychological symptoms of dementia. Concerns over their safety and efficacy in this role have resulted in antipsychotics typically being recommended for short-term usage only when used among dementia patients. However, there is little work examining the duration of antipsychotic treatment in the elderly dementia patient population. To determine the persistence of use of antipsychotics in elderly dementia patients and the role of dose on therapy duration. A retrospective, population-based cohort study using administrative data, including dispensing records from a provincial public drug program, from Ontario, Canada between 2009 and 2012. Elderly dementia patients newly initiated onto antipsychotics were followed until drug discontinuation, death, 2-year follow-up, or end of study. Competing risk analysis was performed to determine time to discontinuation, stratified by categories of initial dose. After 2 years 49.1 % of the cohort (N = 22,927 of 46,695) had discontinued treatment. When stratified by dose, the high-dose group (51.1 % discontinued) discontinued more frequently than the medium- (48.7 % discontinued) and low- (47.5 % discontinued) dose groups (p < 0.0001). Approximately half of elderly dementia patients treated with antipsychotics discontinue within 2 years, with those on higher doses more likely to discontinue. However, the number of patients remaining on therapy represents a serious public health concern. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 2 | 67% |
| United States | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 40 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 7 | 18% |
| Researcher | 7 | 18% |
| Student > Bachelor | 5 | 13% |
| Unspecified | 3 | 8% |
| Student > Doctoral Student | 2 | 5% |
| Other | 6 | 15% |
| Unknown | 10 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 23% |
| Psychology | 5 | 13% |
| Engineering | 4 | 10% |
| Nursing and Health Professions | 3 | 8% |
| Unspecified | 3 | 8% |
| Other | 5 | 13% |
| Unknown | 11 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 July 2016.
All research outputs
#2,966,447
of 23,993,601 outputs
Outputs from Drugs - Real World Outcomes
#31
of 206 outputs
Outputs of similar age
#48,276
of 316,390 outputs
Outputs of similar age from Drugs - Real World Outcomes
#3
of 5 outputs
Altmetric has tracked 23,993,601 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 206 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.8. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 316,390 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.